[go: up one dir, main page]

BR9904054A - Proteìnas que se ligam a diarilsulfoniluréia - Google Patents

Proteìnas que se ligam a diarilsulfoniluréia

Info

Publication number
BR9904054A
BR9904054A BR9904054-9A BR9904054A BR9904054A BR 9904054 A BR9904054 A BR 9904054A BR 9904054 A BR9904054 A BR 9904054A BR 9904054 A BR9904054 A BR 9904054A
Authority
BR
Brazil
Prior art keywords
proteins
diarylsulfonylurea
bind
diarylsulphonylurea
dbps
Prior art date
Application number
BR9904054-9A
Other languages
English (en)
Inventor
Christopher Allen Gabel
Richard John Griffiths
James Frederick Eggler
Mark Anthony Dombroski
Kieran Francis Geoghegan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9904054A publication Critical patent/BR9904054A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)

Abstract

Patente de Invenção: <B>"PROTEìNAS QUE SE LIGAM A DIARILSULFONILURéIA"<D>. A invenção presente refere-se à identificação de proteínas que se liguem a diarilsulfoniluréia (DBPs) como alvos terapêuticos para agentes que suprimem a liberação de mediadores inflamatórios tais como as interleuquinas IL-1 e IL-1<225>.
BR9904054-9A 1998-08-31 1999-08-31 Proteìnas que se ligam a diarilsulfoniluréia BR9904054A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9844898P 1998-08-31 1998-08-31

Publications (1)

Publication Number Publication Date
BR9904054A true BR9904054A (pt) 2000-10-17

Family

ID=22269326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9904054-9A BR9904054A (pt) 1998-08-31 1999-08-31 Proteìnas que se ligam a diarilsulfoniluréia

Country Status (5)

Country Link
US (1) US6461822B2 (pt)
EP (1) EP0987552A3 (pt)
JP (3) JP2000095796A (pt)
BR (1) BR9904054A (pt)
CA (1) CA2280049A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509378A (ja) * 1999-09-14 2003-03-11 ファイザー・プロダクツ・インク ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法
NL1014696C2 (nl) * 2000-03-20 2001-09-28 Stichting Energie Vervaardiging van lage-temperatuur brandstofcel elektroden.
EA007014B1 (ru) * 2000-05-05 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Применение il-18 в качестве диагностического маркера
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
US7374894B2 (en) * 2002-07-16 2008-05-20 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
WO2004031777A1 (en) * 2002-10-03 2004-04-15 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
JP2004298112A (ja) * 2003-03-31 2004-10-28 Japan Science & Technology Agency ヒト固形癌抗原ペプチドとこれをコードするポリヌクレオチド、並びにそれらの利用
WO2012135500A1 (en) 2011-03-29 2012-10-04 The General Hospital Corporation Engineered thioredoxin-like fold proteins
ME03737B (me) * 2015-02-16 2021-01-20 Univ Queensland Sulfoniluree i srodna jedinjenja i njihova upotreba
EP3445756B1 (en) 2016-04-18 2022-07-06 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
BR112019024831A2 (pt) * 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CN120647572A (zh) 2017-07-07 2025-09-16 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
AU2018317798A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545632A (en) 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
AU2646295A (en) * 1994-05-18 1995-12-05 Ligand Pharmaceuticals, Inc. Screening for cytokine modulators
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
US5874248A (en) * 1997-08-21 1999-02-23 Incyte Pharmaceuticals, Inc. Glutathione S-transferase homolog
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
ID27813A (id) * 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis

Also Published As

Publication number Publication date
US6461822B2 (en) 2002-10-08
JP3706353B2 (ja) 2005-10-12
JP2003057227A (ja) 2003-02-26
JP2004339232A (ja) 2004-12-02
EP0987552A3 (en) 2000-06-07
US20020034764A1 (en) 2002-03-21
JP2000095796A (ja) 2000-04-04
CA2280049A1 (en) 2000-02-29
EP0987552A2 (en) 2000-03-22

Similar Documents

Publication Publication Date Title
BR9904054A (pt) Proteìnas que se ligam a diarilsulfoniluréia
BR0116464A (pt) imidazoquinolinas substituìdas com amido éter
BR0012666A (pt) Imidazoimidazóis e triazóis como agentes anti-inflamatórios
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
NO973745D0 (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
BR9902086A (pt) Formulações farmacêuticas.
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
BR9914044A (pt) ésteres tetrahidropirido
BR9906888A (pt) &#34;travessa&#34;
DE60232653D1 (de) Pharmazeutisch wirksame uridinester
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
SE9801494D0 (sv) Novel use
ATE297903T1 (de) Substituierte phenyluracile
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
EP1352072A4 (en) NUCLEIC ACID RELEASE PREPARATIONS
BR9812773A (pt) &#34;alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados&#34;
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
DE69831737D1 (de) Neurotrypsin
BR0317834A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìlico como inibidores mmp 13 seletivos
HN1998000102A (es) Composiciones solubilizadas de sertralina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1994 DE 24/03/2009